| OA01.05LB | Opening the HIV-1 envelope for neutralization and antibody-dependent cellular cytotoxicity | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA14.01 | Improved killing of HIV-infected cells by a combination of three neutralizing and non-neutralizing antibodies | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA14.02 | Unprimed CD8+ lymphocytes promote the maintenance of HIV latency in CD4+ T cells | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA14.04 | Targeting Sphingosine-1-phosphate signaling prevents cell-to-cell transmission of HIV-1 | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PE26.01 | Surge strategies improve HIV testing efficiency and linkage to treatment among female sex workers in Nairobi, Kenya | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PE26.02 | Effect of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection in young adults and reduce HIV transmission in Kenya: A randomized controlled trial | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PE27.01 | Association between Basal Metabolic Index and vaccine-induced HIV-1 adaptive immunity | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PE27.02 | The influence of HIV-1 subtype C LTR genotype on latency potential | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PE27.03 | Impact of baseline variables on time to viral rebound after treatment interruption in acutely treated HIV-1 infected participants | E-poster | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PU28.01 | Findings from an HIV risk behavior assessment among penal and probation population in Ukraine | Publication Only | Therapeutic vaccines, viral reservoirs and eradication/remission |